Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer by Li,  S.L. et al.
PRECLINICAL STUDIES
Antitumor effect of BPR-DC-2, a novel synthetic cyclic
cyanoguanidine derivative, involving the inhibition
of MDR-1 expression and down-regulation of p-AKT
and PARP-1 in lung cancer
Shun-Lai Li & Chia-Hsin Huang & Chih-Chan Lin & Zih-Ning Huang &
Jyh-Haur Chern & Hsiao-Yin Lien & Yong-Yi Wu & Chia-Hui Cheng & Chia-Yu Chang &
Jiunn-Jye Chuu
Received: 19 August 2009 /Accepted: 28 September 2009 /Published online: 5 December 2009
# Springer Science+Business Media, LLC 2009
Summary In our previous study, a series of novel cyclic
cyanoguanidine compounds, eg. 5-substituted 2-
cyanoimino-4-imidazodinone and 2-cyanoimino-4- pyrimi-
dinone derivatives have been successfully synthesized and
showed remarkable cytotoxicity in several cancer cell lines.
In this present study, it is our aim to screen more potential
candidates among the cyclic pyridyl cyanoguanidine com-
pounds (BPR-DC-1, 2, 3) by in vitro and in vivo studies for
the therapy of lung cancer, alternatively. Our results showed
that BPR-DC-2 significantly inhibited proliferation of
tumor cells with an IC50 of 3.60±1.27 and 14.81±
4.23 μM in human lung carcinoma cells, H69 and A549,
respectively by the MTT assay at 48 hr; BPR-DC-2 also
obviously suppressed the tumor proliferation and MDR-1
gene expression, even induced cell apoptosis in the ex vivo
histocultured lung tumor. We further demonstrated that, in
the nude mouse model of metastatic lung cancer, BPR-DC-
2 could diminish the tumor mass, retard the progression of
metastasis, and prolong the survival time. In addition, it
was found that BPR-DC-2 exerted its anti-tumor effects
through the inhibition of MDR-1 gene expression and
down-regulation of tumor anti-apoptosis signals (activated
p-AKT and over-expression of PARP-1) by western blotting
analysis. In conclusion, in this present study we have
demonstrated that BPR-DC-2, derived from a series of
novel synthetic cyclic cyanoguanidine compounds, has
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proved its potential as an anti-tumor drug candidate in
treating lung cancer.
Keywords Cyanoguanidine . Lung cancer . Histoculture .
Nude mouse model . MDR-1 gene
Introduction
Lung cancer has been the leading cause of cancer death for
women in Taiwan since 1996 [1–3]. Several novel
cytotoxic agents (taxanes, gemcitabine, pemetrexed) and
molecular-targeted agents (erlotinib, bevacizumab) im-
proved the survival and quality of life in patients with
advanced stage non-small cell lung cancer (NSCLC) [4].
However, the 5-year survival rate for patients with stage III
NSCLC was still around 10% [5, 6] owing to poor response
of this tumor to conventional chemotherapy [7, 8].
In the late 1990s a new anticancer agent, CHS 828
(the pyridyl cyanoguanidine derivative) was identified by
in vitro cytotoxicity screening assays and in vivo
preclinical studies [9, 10]. Our previous studies have
successfully developed second-generation drugs derived
from CHS 828, which were a series of 5-substituted 2-
cyanoimino-4-imidazodinone and 2-cyanoimino-4-pyrimi-
dinone derivatives, based on a drastic change of the parent
cyanoguanidine core. They exhibited potent cytotoxicity
against a variety of cancer cell lines with IC50 in the
nanomolar range [11, 12].
Recently we have successfully established human tumor
cell lines (PLC/PRF/5) grown in three-dimensional histo-
cultures in vitro. The three-dimensional tumor histocultures
described here has been shown to be a technique that allows
tumor tissues to grow in an in vivo-like way with
maintenance of tissue histology, function and their sensi-
tivity to drug for a long period of time [13]. Several human
tumors such as colorectal, prostate, bladder, gastric, ovarian
and breast cancer have been established as histocultures
[14].
In the present study, highly metastatic lung cancer cell
lines, mouse Lewis lung carcinoma (LL2) cells, human
A549 and H69 cells were used to evaluate a series of novel
cyclic cyanoguanidine compounds in their capabilities of
inhibiting tumor growth. We demonstrated that the activa-
tions of anti-apoptosis signals and multiple drug resistance
(MDR) might play a crucial role in the progression and
metastasis of lung cancer.
To elucidate the mechanisms of novel cyclic cyanogua-
nidine compounds on histocultured LL2 cells we measured
the cell proliferation and cell death in vitro by using the
methods of bromodeoxyuridine (BrdU) incorporation and a
terminal deoxynucleotidyl transferase-mediated deoxyuri-
dine triphosphate nick end labelling (TUNEL). The
expressions of multiple drug resistance (MDR-1) protein
were determined by means of immunohistochemistry
assays. The p53 mutations occur in tumor tissue and may
contribute to multidrug resistance (MDR) in patients and
animals [15, 16]. Murine Lewis lung carcinoma (LL2) and
Human H69 cells carrying defective p53 [17, 18], the
human lung adenocarcinoma A549 cells has wild-type p53
and induced Bax signaling pathway [19].
Furthermore, by using the nude mouse model of lung
cancer we measured the body weight, lung foci, tumor size
and survival time after treatment with the novel cyclic
cyanoguanidine compounds, and the expressions of MDR-1
gene and apoptosis-related proteins (p-AKT and PARP-1)
in the tumor cells by western blotting.
Materials and methods
Chemicals and suppliers
A novel series of N-heterocyclic indolyl glyoxylamides
derivatives of heterocyclic compounds, BPR-DC-1, BPR-
DC-2, and BPR-DC-3 (Fig. 1) were synthesized through
cyclization of 4-pyridyl cyanoguanidines with 2-substituted
chloroacetylchloride or 3-chloropropionylchloride as de-
scribed in our previous publication [20]. Paclitaxel and
doxorubicin were purchased from Calbiochem- Novabio-
chem Co (San Diego, CA, USA). Sterile pig skin collagen
matrix (Spongostan) was purchased from Johnson &
Johnson Medical Co (Gargrave, Skiption, U.K.). MTT [3-
(4,5-dimethylthiazol-2-yle) 2,5-mdiphenyl-tetrazolium bro-
mide], 5-bromo-2′- deoxyuridine (BrdU), proteinase K,
GTP and 1,4- piperazineethane-sulfonate (PIPES) were
from Sigma Chemical Co. (St. Louis, MO, USA). L-
glutamine, sodium pyruvate, fetal bovine serum (FBS),
gentamycin, Dulbecco’s modified eagle medium (DMEM),
minimal essential medium (MEM), MEM non-essential
amino acids solution and MEM vitamin solution were
purchased from Invitrogen, Co (Grand Island, NY, USA).
Monoclonal mouse antibody against BrdU, streptavidin-
biotin-horseradish peroxidase detection system LSAB2, and
3-3′-diaminobenzidine (DAB) were obtained from DAKO,
Co. (Carpinteria, CA, USA). The ApopTag® apoptosis
detection kit was from Intergen Inc (Purchase, NY, USA).
The silanized slides were from Muto Pure Chemicals Co.
(Tokyo, Japan). Cryostat /microtomes, cryomatrix and
histomount (xylene substitute mountant) were from Shan-
don (Pittsburgh, PA, USA). The CEA kit was from Pan
pacific tech company (Double lake, Missouri, USA) Rabbit
polyclonal antibodies- MDR-1 and mouse monoclonal
antibodies p-AKT, PARP-1, β-actin, HRP-anti-rabbit IgG
and HRP-anti-mouse IgG were from Santa Cruz Biotech-
nology, Inc (Santa Cruz, CA, USA). Nitrocellulose paper
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membrane was purchased from NEN Life Science Products
(Boston, Massachusetts, USA).
In vitro anti-proliferative assay (MTT assay)
Lung cancer cell lines, A549, H69 (human) and LL-2
(mouse) were purchased from Food Industry Research
and Development Institute (Hsin Chu, Taiwan, R.O.C).
The cell lines were cultured in 96-well flat-bottomed
microtiter plates supplemented with 10% heat-inactivated
fetal calf serum (FCS), 100 U/ml penicillin and 100 U/ml
streptomycin in a humidified atmosphere containing 95%
air and 5% CO2 at 37°C in a humidified incubator. The
cells cultured in the exponential growth phase were treated
with different concentrations (0.1–100 μg/ml) of novel
cyclic cyanoguanidines compounds (BPR-DC-1, 2, 3),
paclitaxel and doxorubicin at a density of 5,000 cells/
200 μl/well. After 72 h of incubation, the in vitro anti-
proliferative effects of these compounds were determined
by the MTT assay (at 570 nm) and the cell viability was
expressed as a percentage of the control (untreated) cells
(% of control).
The preparations of nude mouse model of lung cancer
The 6 to 8 weeks old of male athymic nude mice (Balb/c)
were purchased from National Laboratory Animal Center
(Taipei, Taiwan) and housed under aseptic conditions for
tumor inoculation. All animals were maintained in laminar
flow cabinets under specific pathogen-free conditions in
facilities approved for Accreditation of Laboratory Animal
Care and in accordance with Institutional Animal Care and
Use Committee (IACUC) of the Animal Research Com-
mittee in Chi-Mei Medical Center, Tainan, Taiwan. Cages,
bedding, food, and water were autoclaved and animals were
maintained on a daily 12-hour light/12-hour dark cycle. LL-
2 lung cancer cells were diluted in cold Matrigel (1:1), and
nude mice were inoculated subcutaneously with 5×106
cells/mice on the flanks.
Assay of ex vivo tumor histocultures
Fresh surgically removed tumor specimens from mice
bearing with lung cancer cells (LL-2) were prepared for
ex vivo histocultures as described previously [21]. The
tumors were kept in MEM after surgical excision, placed on
ice, and prepared for histocultures within 2 h. First, the
collagen gels were presoaked overnight in culture medium,
and then cut into 1 cm pieces and placed in 6-well plates.
The tumors were dissected into pieces of 1 to 2 mm in
diameter. Four to six pieces of tumors were placed on each
collagen gel matrix and cultured in medium consisting of a
mixture of MEM:DMEM (1:1), 2 mM L-glutamine, 10%
FBS, 1 mM sodium pyruvate, 0.1 mM non-essential amino
acids, and 40 μg/ml gentamicin, PH=7.4. The histocultures
were kept in a humidified atmosphere containing 95% air
and 5% CO2 at 37°C in a CO2 incubator from Binder
(Tuttlingen, Germany). Eight ml culture medium was added
into each well to barely cover the surface of the gel. After
cultivation for 2 to 4 days, the histocultures were exposed
to various concentrations of 0.1 to 100 µM of synthetic
cyclic cyanoguanidines compounds and doxorubicin for 48
and 96 h. After treatment the histocultures were then
incubated with 40 μM BrdU for 48 hr, washed 3 times with
PBS, fixed in 10% neutralized formalin.
Immunohistochemical measurement of cell proliferation
Immunohistochemical detection of the incorporated BrdU
was performed using the BrdU antibody M744 (1:250
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Fig. 1 Chemical structures of
cyclic cyanoguanidine com-
pounds, BPR-DC-1, BPR-DC-2,
BPR-DC-3 and CHS 828 Three
synthetic novel cyclic
cyanoguanidine compounds,
BPR-DC-1, BPR-DC-2 and
BPR-DC-3 were compared with
the original one, CHS828
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dilution). BrdU-labeled tumor cells were visualized in
brown and the tissue sections were counterstained with
Mayer’s hematoxylin from Shandon (Pittsburgh, PA). As
previously reported, proliferating cells were identified by
brown nuclear staining and counted for each tissue section.
The total cell numbers were also counted in the same
sections by the number of nuclei per square millimeter
using an eyepiece reticule. A BrdU labeling index,
expressed as a percentage of dividing the number of
BrdU-labeled nuclei by the total number of nuclei, was
calculated for each tissue section.
Detection of tumor cell death by TUNEL staining
ApopTag®detection kit was used to stain for apoptotic
dying cells in the histocultured LL-2 cell. Dead or dying
cells were detected by terminal deoxynucleotidyl transfer-
ase (TdT)-mediated dUTP nick-end labeling (TUNEL)
staining as previously described [22] with minor modifi-
cations. Briefly, the tissue sections were deparaffinized,
rehydrated, and then digested with 20 µg/ml of proteinase
K for 15 min at room temperature. Reactions with the TdT
enzyme, digoxigenin-dUTP and anti-digoxigenin peroxi-
dase conjugates followed by the peroxidase substrate,
H2O2 and then DAB color reaction were performed
according to the manufacturer’s procedures. Positive
controls were obtained via DNase (Boehringer Mannheim)
treatment. TdT was omitted as a negative control. The
tissue sections were then counter-stained with hematoxy-
lin, examined under light microscopy, and photographed
at 400-fold magnification using a digital camera. TUNEL-
positive dead or dying cells were identified by the brown-
labeled nuclei. The number of TUNEL-positive cells and
the total number of tumor cells in the observation field
were counted. Percentage of cell death was calculated by
dividing the number of TUNEL-positive cells by the total
number of tumor cells.
The measurements of body weight, lung foci, tumor size
and survival analysis of the nude mouse model of lung
cancer after treatment with BPR-DC-2
Balb/c nude mice were purchased from National Laboratory
Animal Center, Taipei, Taiwan. Upon arrival, the animals
were kept in the animal room for 14 days to adapt to the
environment. They were housed four per cage under
standard laboratory conditions at an ambient temperature
(23±2 °C) and given a solid diet and tap water ad libidum.
The study was conducted in accordance with the guideline
for the care and use of Laboratory Animals by the Animal
Research Committee in Chi-Mei Medical Center, Tainan,
Taiwan. Animals were aclimatized to the laboratory con-
ditions prior to the experiments and all experiments were
carried out between 10:00 AM and 05:00 PM. On the 15th
day, the Balb/c nude mice were injected intravenously via
tail vein with 1×107 LL2 cells (from the cell culture
described above) to induce metastatic Lewis lung carcino-
ma as described previously [23]. The recipient mice were
randomly divided into two groups (ten mice for each
group): control group treated orally with saline, and BPR-
DC-2 group treated with 10 mg/kg/day BPR-DC-2 for 3
consecutive days by intravenous (i.v) injection. Body
weight, lung weight and lung foci of each mouse were
measured daily before their death or sacrifice. The date of
death was recorded and the survival rate of experimental
mice was calculated for survival analysis. The bloods of all
mice were collected for CEA analysis.
Western blot analysis for MDR-1 and apoptosis related
proteins in the nude mouse model of lung cancer
After i.v. administration of BPR-DC-2 for day 0, 21, 34, 40
and 51, the tumor bearing nude mice were sacrificed by
decapitation. The lung tumors were rapidly removed,
immediately frozen in liquid nitrogen and stored at −80°C
Table 1 The growth inhibition of lung cancer cells by novel cyclic cyanoguanidine compounds and anti-tumor agents The growth inhibition of lung
cancer cells (LL2, H69, A549) were measured by IC50 (μM) with MTT assay after 48 and 72hs treatments with a series of novel cyclic
cyanoguanidine compounds, BPR-DC-1, BPR-DC-2, BPR-DC-3, and anti-tumor agents, doxorubicin and paclitaxel. Generally an IC50 value<
10 μM is considered as active. * denotes p<0.05, as compared with doxorubicin and # denotes p < 0.05, as compared with paclitaxel
Lung cancer Cell line Time Growth inhibition, IC50(μM)
BPR-DC-1 BPR-DC-2 BPR-DC-3 Doxorubicin Paclitaxel
Mouse LL-2 48 hr >100 >100 >100 >100 >100
72 hr 31.61±8.523 6.82±1.74# 7.22±3.11# 0.15±0.02 >100
Human H69 48 hr – 3.60±1.27# – 7.82±2.75 9.64±2.11
72 hr – 0.76±0.11 – 2.81±0.94 82.54±9.50
A549 48 hr >100 14.81±4.23*# >100 >100 >100
72 hr >100 2.47±0.68*# 1.22±0.27*# >100 23.86±7.12
able 1 The growth inhibition of lung cancer cells by novel cyclic
cyanoguanidine compounds and anti-tumor agents The growth inhibition
of lung cancer cells (LL2, H69, A549) were measured by IC50 (μM) with
MTT assay after 48 and 72hs treatments with a series of novel cyclic
cyanoguanidine compounds, BPR-DC-1, BPR-DC-2, BPR-DC-3, and
anti-tumor agents, doxorubicin and paclitaxel. Generally an IC50 value
<10 μM is considered as active. * denotes p<0.05, as compared with
doxorubicin and # denotes p < 0.05, as compared with paclitaxel
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until use. The segments were homogenized with a polytron
homogenizer and sonicated in ice-cold 20 mM Tris buffer
(pH 7.0) containing 1 mM phenylmethylsulfonylfluoride
(PMSF) 20 ml/g tissue. These homogenates were centri-
fuged for 15 min at 3000×g, and then the resulting
supernatant was centrifuged at 27000×g for 30 min. The
pellets were resuspended in buffer solutions containing
300 mM mannitol and 40 mg/ml PMSF (pH 7.5), and the
protein concentrations were determined. Samples were
separated on a 10% polyacrylamide gel, which was then
transferred to Nitrocellulose paper membrane. Blots were
blocked with BSA in PBST (11.24 g, Na2HPO4, 2.87 g,
NaH2PO4 and 0.1% Tween 20) for 2 hrs at room
temperature. After blocking, membranes were incubated
for 1 hr at room temperature in wash buffer with either the
anti-MDR-1 antibody (1:800), anti-P-AKT antibody (1:500)
or anti-PARP-1 antibody (1:500), followed by four times
10 min washes. Horseradish peroxidase-conjugated anti-
rabbit IgG antibody was diluted to 1:5000 in wash buffer
and incubated with blots for 1 hr at room temperature,
followed by washes four times every 10 min, and detected
by enhanced chemiluminescence (FUJIJILM LAS-3000).
And the β-actin signal was used to normalize protein
loading.
Data analysis
Dose response curves were created by Sigma plot
software, and IC50 values were determined graphically
from the plots. Drug activities were expressed as mean
±SEM. One-way ANOVA test (SPSS) was used to
evaluate the significance of the difference between
treatment groups.
Results
The growth inhibition of lung cancer cells treated
with novel cyclic cyanoguanidine compounds
and anti-tumor drugs
Our previous study have shown that the cyclic cyano-
guanidine compounds with different chain length of the
alkyl linker and heterocyclic ring size exhibited different
anti-proliferation effects in various cancer cell lines.
Three cyclic cyanoguanidine compounds, BPR-DC-1,
BPR-DC-2 and BPR-DC-3 (Fig. 1) were selected as the
representatives of the Indolyl Glyoxylamide derivatives.
The various concentrations of BPR-DC-1, BPR-DC-2,
BPR-DC-3 and anti-tumor drugs, doxorubicin and pacli-
taxel, were tested in several lung cancer cell lines, LL2
(mouse), H69 and A549 (human) respectively at 48 and
72 hr. As shown in Table 1, BPR-DC-2 exhibited the most
prominent inhibition of tumor growth dose and time
dependently by in vitro assay of MTT. At 48 hr, all the
cyanoguanidine compounds did not inhibit significantly
the growth of mouse LL-2 cells. However, BPR-DC-2
inhibited the growth of human lung carcinoma cells, H69
and A549 with an IC50 of 3.60±1.27 μM and 14.81±
4.23 μM respectively at 48 hr. At 72 hr, both BPR-DC-2
and BPR-DC-3 inhibited the growth of mouse LL-2 cells
with an IC50 of 6.82±1.74 μM and 7.22±3.11 μM
respectively.
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Fig. 2 The in vitro anti-proliferative effects of cyclic cyanoguanidine
compounds and doxorubciin and levels of CEA on histocultured lung
cancer cells The surgically removed tumor specimens from mice
implanted with lung cancer cells (LL-2) were treated with BPR-DC-1,
2, 3 and doxorubicin (10 μM) for 48 and 96 hours. a The in vitro anti-
proliferation effects of these compounds were assayed by MTT and b
the levels of CEA (carcinoembryonic antigen) in cultured medium of
treated groups (n=6) and control group (n=6) was determined. Data
were expressed in mean ± SE. * denotes p<0.05 , as compared with
the control group
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The inhibitive effects of novel cyclic cyanoguanidine
compounds on tumor proliferation and levels of CEA
in the histoculture of lung cancer
To evaluate whether novel cyclic cyanoguanidine com-
pounds inhibit tumor proliferation in the three-dimensional
histocultures of lung cancer, MTT assay was used for
testing their efficacy. After incubation for 48 and 96 h, the
tumors were tested for their response to the treatment of
BPR-DC-1, 2, 3 and doxorubicin (Fig. 2a). The BPR-DC-2
at the concentration of 10 μM were more efficacious than
doxorubicin (∼50% v.s.∼30%). The lung specific tumor
marker carcinoembryonic antigen (CEA) is secreted from the
histoculture of lung cancer cells. The level of medium CEA
was reduced in the treated groups (BPR-DC-1, 2, 10 μM) as
compared to vehicle control group at 96 h, although no
significant difference was observed at 48 h (Fig. 2b).
The expressions of BrdU, TUNEL and MDR-1
in the histoculture of lung cancer
The histocultured LL2 tumor cells treated with BPR-DC-
2 at concentrations of 1 and 10µM were evaluated for
their immunohistochemical analyses of BrdU, TUNEL
and MDR-1 protein (Fig. 3A). The total cell number
(hematoxylin-labeled and antigen-labeled) and the number
of antigen-labeled cells (brown) were observed. The
representative photomicrographs of BrdU-labeled cells
(Fig. 3Aa–c), TUNEL-labeled cells (Fig. 3Ad–f) and
MDR-1-labeled cells (Fig. 3Ag–i) were identified and
counted at 400Χ magnification. The ratio of antigen-
labeled cells to total cells was expressed as a percentage of
controls (Fig. 3B). Our data revealed that BPR-DC-2
significantly suppressed dose-dependently the tumor pro-
liferation (Fig. 3B, a) and MDR-1 protein expression
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Fig. 3 The staining photomicrographs and percentages of BrdU,
TUNEL and MDR-1 labeled lung cancer cells treated with BPR-DC-2
in ex vivo histoculturs. Histocultured lung cancer LL-2 cells were
treated with BPR-DC-2 at concentrations of 1 and 10 µM for 96 hr. A
The representative staining photomicrographs of BrdU (a–c), TUNEL
(d–f) and MDR-1 (g–i). The proliferating cells are BrdU-labeled in
brown, the dead or dying cells are TUNEL-labeled in brown, and the
cells expressing MDR-1 are labeled in brown. B The percentages of
BrdU-labeled proliferating tumor cells (n=5), TUNEL-labeled tumor
cells (n=5) and MDR-1- labeled tumor cells (n=5) in total lung cancer
cells. Data were expressed in mean±SE. * denotes p<0.05 and **
denotes p<0.01, as compared with the control group
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(Fig. 3Bc), and increased tumor cell death (Fig. 3Bb) in
the histocultured lung cancer cells.
The effects of BPR-DC-2 on body weight, tumor size, lung
foci and survival time of the nude mice bearing with lung
cancer
It has been reported that the metastatic foci in the lungs of
the nude mice could be induced 4–5 weeks after injection
of highly metastatic Lewis lung carcinoma (LL2 cells) [24].
The tumor growth was monitored daily from day 21 to day
51. The number of surface lung tumor nodules was
detectable at day 21, and the metastatic foci were clearly
observed at day 38 and 51 after injection of tumors. Our
data revealed that the treatment of BPR-DC-2 (10 mg/kg)
significantly delayed the loss of body weight (data not
shown) and reduced the size of metastatic tumors at day 21
(2.1 g) and day 51 (1.4 g) as compared with saline group at
day 21 (2.6 g) by histopathological observations (Fig. 4a, b).
In addition, BPR-DC-2 (10 mg/kg) was found to retard the
progression of LL2 cells by decreasing the number of lung
tumor foci (Fig. 4c). Furthermore, BPR-DC-2 (10 mg/kg)
prolonged the mean survival time of nude mice bearing with
LL2 cells (Fig. 4d). All these results indicated that BPR-DC-
2 could significantly inhibit the tumor growth in the nude
mouse model of lung cancer.
The expressions of MDR-1 and apoptosis- related
proteins in the lung tumor cells of nude mice treated
with BPR-DC-2
The expressions of MDR-1, p-AKT, and PARP-1 protein
were measured in the saline group on days 0 and 21 and in
BPR-DC-2 (10 mg /kg) treated group on day 21, 34, 40 and
51 (Fig. 5). It was found that the treatment of BPR-DC-2
(10 mg/kg) could significantly reduce the levels of MDR-1,
p-AKT, and PARP-1 time-dependently at day 21, 34, 40
and 51 as compared with saline group at day 0, and more
significant when compared with saline group at day 21. For
the three protein expression in lung tissue, the normal group
is not significantly different from the saline group at day 0
(data not shown).
Discussion
In this present study we have demonstrated that among a
series of novel synthetic cyclic cyanoguanidine compounds
(BPR-DC-1, 2 and 3), BPR-DC-2 significantly inhibited the
proliferation of tumor cells and induced their apoptosis in
both cell lines and ex vivo histocultures of lung cancer.
Similarly, in the nude mouse model of lung cancer, the
treatment of BPR-DC-2 could diminish the tumor mass,
retard the progression of metastasis, and prolong the
survival time. Recent studies have shown, the p-Akt was
overexpressed in lung tumor, if the p-Akt down-regulate,
the result indicated that caused apoptosis. These findings
are in accordance with previous studies [24, 25], which that
TUNEL assay was used to stain for apoptotic dying cells.
Poly (ADP-ribose) polymerase-1 (PARP-1)protein play a
role in the subsequent apoptotic death of cancer cell lines
[26].
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Furthermore, we have found that BPR-DC-2 exerted its
anti-tumor effects through the inhibition of MDR-1 gene
expression and down-regulation of anti-apoptosis signals
(activated p-AKT and related expression of PARP-1).
CHS 828 (N-(6-chlorophenoxyhexyl)-N'cyano-N″-4-
pyridylguanidine), a pyridyl cyanoguanidine, has been
shown to exert a significant anti-tumor effects in vitro and
in vivo, and was planning for phase II studies [27, 28].
Although CHS 828 has been shown to inhibit NF-kappaB
translocation [29], cause regression of NYH small cell lung
cancer [30] and increase long-term survival (>6 months) in
nude mice bearing with NYH tumors [31], its severe side
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effects e.g. vomiting, haematuria, leucopenia and thrombo-
cytopenia, accompanied with increasing dosage [32] would
hinder its further clinical studies. Based on the structure of
CHS 828, its analogues with appropriate chain length of the
alkyl linker and a pyridine-containing heterocyclic ring
compounds were prepared in this study for testing their
anti-tumor effects on the lung cancer cell lines. Previous
study has shown that the cyanoguanidine moiety and the
chain length was considerably important for their anti-
tumor effects on various cancer cell lines other than lung
cancer cells [32]. Indeed, in this study we did find that the
cyanoguanidine derivatives, BPR-DC-2 and BPR-DC-3,
with a chain length of seven carbons inhibited more tumor
growth in mouse lung carcinoma (LL2 cells) and human
lung carcinoma (H69 and A549 cells) than BPR-DC-1, a
compound with a chain length of five carbons. It is
implicated that the chain length related hydrophobicity
and conformational flexibility may influence the drug
influx through its interaction with cell membranes. Further-
more, we also found that BPR-DC-2, a cyclic cyanoguni-
dine derivative with methyl group in 5-position, showed
more inhibition of tumor growth in human lung cancer cells
lines (H69, A549) than BPR-DC-3 with bulky 5-aryl group
substitution. On the contrary, it has been reported that 2-
cyanoimino-4-imideazolidinone derivatives with bulky aryl
group in the 5-position was more efficacious against human
colon cancer cells (DLD1) and human liver cancer cells
(HEPG2) than those with methyl group in the 5-position
[33]. Nevertheless, these findings all suggested that the
chemical structures with functional groups (either methyl or
aryl group) in 5-position of the 2-cyanoimino-4 imidazoli-
dinone derivatives might play an important role in
enhancing their anti- tumor effects.
In previous study we have demonstrated that the human
hepatoma cells can be successfully cultured in the three-
dimensional histoculture system and used for the pharma-
cological studies in our laboratory [34, 35]. In this present
study we used both monolayer cells and histocultured cells
of lung cancer to investigate the anti-tumor effects of cyclic
cyanogunidine compounds. By using the MTT assay as
end-point we have found that BPR-DC-2 on 48 and 96 hr
was more efficacious than doxorubicin in the histoculture
system. Nevertheless, unlike monolayer cell culture, the
proliferation and death of cells in the histoculture system
may not be easily determined by MTT assay. By using the
assays of BrdU and TUNEL we further found that BPR-
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DC-2 significantly suppressed the tumor proliferation and
induced cell death in the histocultured tissues of lung
cancer dose-dependently (Fig. 3A). These findings are in
accordance with other’s studies, which suggested that the
anti-tumor agents such as paclitaxel might enhance their
penetrations in human tumors through the drug-induced
apoptosis and subsequent rapid drug uptake [36–38] and
even distribution in the tumor cells [36, 39].
Carcinoembryonic antigen (CEA) is well known as a
tumor marker for the lung adenocarcinoma. Elevated levels
of CEA have been implicated in various biological aspects
of neoplasia such as tumor cell adhesion, metastasis and
anti-apoptosis functions [40, 41]. In this study, we noted
that the treatment of BPR-DC-2 (10 μM) could decrease the
medium levels of CEA at 96 h, which is well correlated
with the corresponding MTT assay in the histocultured
tissues of lung cancer (Fig. 2). It has been reported that the
MDR phenotype is associated with the increasing drug
efflux from cells that is mediated by an energy-dependent
mechanism and a blockage of apoptosis-inducing pathway,
which is also one of the major mechanisms of multi-drug
resistance in cancer cells [42]. In this present study we
indeed found that BPR-DC-2 significantly potentiated its
anti-tumor effects partially through the reduced expression
of MDR-1 gene.
In this present study, an in vivo nude mouse model of
experimental Lewis lung carcinoma (LL2) metastasis was
employed. Our results showed that the treatment of BPR-
DC-2 could significantly inhibit tumor growth in the nude
mice bearing with lung cancer. BPR-DC-2 (10 mg/kg/day)
significantly reduced tumor volume by 19±5% and 60±
13% at days 21 and 51 respectively after tumor implanta-
tion. Furthermore, a close correlation between surface lung
tumor nodules and survival time was observed. Our results
were also in accordance with previous study, which showed
that the administration of CHS 828 at doses ranging from
20 to 50 mg/kg p.o. in mice with NYH SCLC tumors could
reduce the tumor weight by 80% and increase survival time
by more than 100%, as compared with controls [30].
Furthermore, in molecular level, we have found that the
treatment of BPR-DC-2 (10 mg /kg) significantly reduced
the levels of phosphorylated AKT (p-AKT), PARP-1 in a
time-dependent fashion, as compared to the treatment of
saline. As shown in Fig. 5, the treatment of BPR-DC-2
(10 mg /kg) at day 40 and 51 remarkably suppressed the
expression of p-AKT as compared with the saline control at
day 0, which was in parallel with a decrease in the over-
expression of PARP-1. It is acknowledged that the family
of Akt kinase, AKT-1, is a downstream mediator of
phosphatidylinositol 3-kinase (PI3K) and a signal transduc-
tion protein that plays a central role in key processes of
tumorigenesis [43–46]. Many studies have revealed a
prognostic and/or predictive role of Akt phosphorylation
in breast, prostate and non-small cell lung cancer [44–47].
The targets of Akt phosphorylation include those proteins
essential for the regulation of cell cycling and suppres-
sion of programmed cell death [47]. It was reported that
the positive rate of p-AKT was significantly higher in
NSCLC than in non-cancerous lung disease [48]. In
another hand, PARP-1 (Poly (ADP-ribose) polymerase-1)
is well known as the founding member of a family of
enzymes that catalyze the addition of ADP-ribose units to
proteins that mediate pathways of DNA repair. It was
reported that the cytotoxic activity of CHS 828 could be
modulated by the ADP-ribosylation inhibitor 3-ABA in
the nude mice xenografted with human non-small cell
lung tumor [30, 49], which is in accordance with our
findings that treatment of BPR-DC-2 (10 mg /kg)
significantly reduced the levels of PARP-1 in a time-
dependent fashion.
In summary, BPR-DC-2, a novel synthetic cyclic
cyanoguanidine derivative, has shown its potential as an
anti-tumor drug candidate. It significantly inhibited prolif-
eration of tumor cells and induced their apoptosis in the
lung cancer cell lines and ex vivo histocultures. In the nude
mouse model of metastatic lung cancer, the treatment of
BPR-DC-2 could suppress the tumor mass, retard the
progression of metastasis, and prolong the survival time.
Its anti-tumor effects were through the inhibition of MDR-1
gene expression and down-regulation of tumor anti-
apoptosis signals (activated p-AKT and over-expression of
PARP-1).
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